On the basis of preclinical studies, several case reports have demonstrated that the combination of gefitinib/erlotinib and osimertinib was beneficial to EGFR-mutated NSCLC patients harboring T790M in trans with C797S [109–111]. Here, EGFR is linked to non-small cell lung carcinoma.